We are excited to announce new featured audiences at China [email protected] Hamburg! Apply for company presentation (Pitch and Match) now and pitch your latest innovations to potential investors and partners.
Jiangsu Hengrui Medicine: a leading biopharmaceutical company based in China with annual net sales of over $2.5 billion in 2018, and has over 130 ongoing clinical trials. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia, Japan, and Germany.
News: June 17, 2019 – Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announced an exclusive agreement to develop and commercialize Mycovia’s investigational drug, VT-1161 in China. Hengrui will pay Mycovia $7.5 million in development funding, and commits to $9 million in development milestones and up to $92 million in potential sales milestones.
Senior Manager of BD
Senior Director and China Head of Business Develop
BioSense was established to address the business needs of the global biopharmaceutical market with a focus on China, Europe, and the U.S. The organization’s mission is to bridge the gap between undercapitalized biopharmaceutical projects, companies, and investors.
News: April 16, 2019 – BioSense acquired Greater China rights of RX-3117 from Rexahn in a deal potentially worth $226 million.
CEO and President
Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small-molecule drugs to treat liver diseases and cancers. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets.
News: Jun 24, 2019 – GENFIT and Terns Pharmaceuticals announce a $228MM strategic partnership to develop and commercialize Elafibranor in Greater China.
Director, Business Development and Finance
Since the company’s foundation in 2005, the Apogenix team has developed a promising portfolio of innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. These protein therapeutics target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response, and thus have the potential to transform the treatment of oncological and malignant hematological diseases.
News: July 15, 2015 – Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China.
VP, Business Development